ASO Therapy Targeting STAU2 to Inhibit Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Regulating the PALLD‐Mediated EMT Signaling Pathway. Here, STAU2 is linked to pancreatic ductal adenocarcinoma.